Youngwoo Jang
心脏内科 Youngwoo Jang Favorite Doctor
  • SpecialtyInterventional and heart failure
  • Site
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM         Absent  
PM   Present        
Clinical Interests

Cardiovascular intervention
Acute myocardial infarction
Angina and heart failure
Pulmonary hypertension
Atrial fibrillation

Education
Education
Gachon University, MMs
Stanford University, Cardiovascular Medicine, Postdoc
Career
Career
Korean Military Service
Gachon University Gil Medical Center, Intern
Department of Internal Medicine, Gachon University Gil Medical Center, Resident
Department of Cardiology, Gachon University Gil Medical Center, Clinical Instructor
Postdoc at Cardiovascular Institute, Stanford Medicine, CA, USA
Department of Cardiology, Gachon University Gil Medical Center, Clinical Assistant Professor
Department of Cardiology, Gachon University Gil Medical Center, Assistant Professor
More
Community
Community
More
Training
Training
License
License
Medical License
Internal Medicine Specialist
Cardiology board certification
Youngwoo Jang
Paper
Paper
2023 Jang AY, Lee HH, Lee H, Kim HC, Chung WJ. Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018. Korean Circ J. 2023;53:e18. https://doi.org/10.4070/kcj.2022.0231
2022 Jang AY, Kim M; Oh, PC, Suh SY, Lee K, Kang WC, and Han SH, Long-term Clinical Outcomes and Its Predictors Between 1- and 2-stent Strategy in Coronary Bifurcation Lesions: A Baseline Clinical and Lesion Characteristic Matched Analysis, Circ J. Jul, 2022. (accepted)
2022 Jang AY, Oh PC, Kang JM, Park JH, Kang WC. Extensive complex thoracoabdominal aortic aneurysm salvaged by surgical graft providing landing zone for endovascular graft: A case report. World J Clin Cases. May 26, 2022; 10(15): 5005-5011 [DOI: 10.12998/wjcc.v10.i15.5005]
2022 Cha JJ, Jang AY (Co-first author), and Ahn TH et al. A Comparative Analysis of Two Biolimus-Eluting Biodegradable Stents: Evaluation of the Equivalence of 6 Months Versus 12 Months of DAPT Following Biolimus-Eluting Stent Implantation in Acute Coronary Syndrome (EQUUS) . J Cardiovasc Interv. 2022 Apr;1(2):61-71.
2022 Jang AY, Seo JD, Kang WC, Chung WJ, and Park YM. Unexpected paced wide QRS complex rhythm after successful implantation of cardiac resynchronization therapy; what is the mechanism? J Electrocardiol. 2022 Apr 8;73:8-11. doi: 10.1016/j.jelectrocard.2022.03.014.
2022 Jang, A.Y.; Kim, M.S.; Lee, J.; Seo, J.; Shin, Y.H.; Oh, P.C.; Suh, S.Y.; Lee, K.; Kang, W.C.; Ahn, T.; et al. Real-world Treatment Selection Factors and 7-year Clinical Outcomes Between Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Left Main Disease. J. Clin. Med. 2021, 10, x. https://doi.org/10.3390/xxxxx [Accepted. First author, IF 4.24]
2022 Jang, A.Y.; Kang, W.C.; Park, Y.M.; Ha, K.; Seo, J.; Oh, P.C.; Lee, K.; Moon, J. The Thromboembolic Predictability of CHA2DS2-VASc Scores Using Different Echocardiographic Criteria for Congestive Heart Failure in Korean Patients with Nonvalvular Atrial Fibrillation. J. Clin. Med. 2022, 11, 300. https://doi.org/10.3390/ jcm11020300. [First author, IF 4.24]
2021 Jang, A.Y.; Yu, J.; Oh, P.C.; Kim, M.; Suh, S.Y.; Lee, K.; Han, S.H.; Kang, W.C. Real-World Long-Term Clinical Outcomes of Ultrathin Strut Biodegradable Polymer Drug-Eluting Stents in Korean ST-Segment-Elevation Myocardial Infarction (STEMI) Patients with or without Acute Heart Failure Undergoing Primary Percutaneous Coronary Intervention. J. Clin. Med. 2021, 10, 5898. https://doi.org/10.3390/jcm10245898 [ First author, IF 4.24]
2021 Jang AY, Scherer PE, Kim JY, Lim S, and Koh KK. Adiponectin and cardiometabolic trait and mortality: where do we go?. Cardiovasc Res (2021) 00, 1–11 doi:10.1093/cvr/cvab199. Online ahead of print. [First author, IF 10.1]
2021 Oh S, Jang AY (co-first author), Chae S, Hwang D, Byun K, and Chung WJ. Comparative Analysis on the Anti-inflammatory/immune Effect of Mesenchymal Stem Cell Therapy for the Treatment of Pulmonary Arterial Hypertension. Sci Rep. 2021 Jan 21;11(1):2012. PMID: 33479312 PMCID: PMC7820276 DOI: 10.1038/s41598-021-81244-1 [Co-first author, Impact factor: 3.99]
2021 Jang AY, SH Jo, and KK Koh. Emerging New Lipid-Lowering Therapies in the Statin Era. Cardiometab Syndr J. 2021 Mar;1(1):66-75.
2021 Jang AY and KK Koh. Left Atrial Thrombus and Multiple Infarcts. Cardiometab Syndr J. 2021 Mar;1(1):114-115.
2021 Jang AY, Lee JS, Oh PC, Park CH, and Koh KK. Cardiogenic Shock due to Acute Myocardial Infarction: Successfully Recovered with Aggressive Interventions. Cardiometab Syndr J. 2021 Sep;1(2):183-187.
2020 Jang AY, Lim S, Jo SH, Han SH, and Koh KK. New Trends in Dyslipidemia Treatment. Circ J. 2020. doi:10.1253/circj.CJ-20-1037(In press) [First author, IF 2.74)
2020 Jang AY and Suh SY. Extreme venous letting and cupping resulting in life-threatening anemia and acute myocardial infarction: a case report. World Journal of Clinical Cases. 2020 Dec 26;8(24):6432-6436. PMID: 33392327 PMCID: PMC7760420 DOI: 10.12998/wjcc.v8.i24.6432. [First author, IF 1.0]
2020 Jang AY, Kim B-G, Kwon S, Seo J, Kim HK, Chang H-J, et al. (2020) Prevalence and clinical features of bone morphogenetic protein receptor type 2 mutation in Korean idiopathic pulmonary arterial hypertension patients: The PILGRIM explorative cohort. PLoS ONE 15(9): e0238698. https://doi.org/10.1371/journal.pone.0238698 [First author, Impact factor: 2.74]
2020 Jang AY, Oh YJ, Lee SI, Lim OK and Suh SY. Femoral neuropathy following venoarterial-extracorporeal membrane oxygenation therapy: a case report. BMC Cardiovasc Disord. 2020;20. [First author, Impact factor: 2.16]
2020 Jang AY, Han SH, Sohn IS, Oh PC and Koh KK. Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―. Circ J. 2020. [First author, IF 2.7]
2020 Kwon T-G, Jang AY (co-first), Kim SW, Hong YJ, Bae J-H, Lee SY, Kim S-H and Han SH. Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study. Trials. 2020;21. [Co-First author, IF 2.3]
2020 Jang AY, Ryu J, Oh PC, Moon J and Chung WJ. Feasibility and Applicability of Wireless Handheld Ultrasound Measurement of Carotid Intima-Media Thickness in Patients with Cardiac Symptoms. Yonsei Med J. 2020;61:129-136. [First author, IF 1.5]
2020 Jang AY and Shin MS. Echocardiographic Screening Methods for Pulmonary Hypertension: A Practical Review. J Cardiovasc Imaging. 2020;28:1-9.
2019 Jang AY and Chung WJ. Current status of pulmonary arterial hypertension in Korea. Korean J Intern Med. 2019;34:696-707. [First author, IF 2.8]
2019 Jang AY, Kim S, Park SJ, Choi H, Oh PC, Oh S, Kim KH, Kim KH, Byun K, Chung WJ and Investigators P. A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort. Clin Hypertens. 2019;25:21.
2018 Jang AY, Yu J, Park YM, Shin MS, Chung WJ and Moon J. Cardiac Structural or Functional Changes Associated with CHA2DS2-VASc Scores in Nonvalvular Atrial Fibrillation: A Cross-Sectional Study Using Echocardiography. J Cardiovasc Imaging. 2018;26:135-143. [First author]
2018 Jang AY, Yu J, Oh PC, Lee K, Kang WC, Han SH, Ahn T, Suh SY and Yang J. Radial Motor Nerve Palsy Following Transradial Coronary Intervention. Circ Cardiovasc Interv. 2018;11:e007203. [First author, IF 6.9]
2018 Jang AY, O'Brien C, Chung WJ, Oh PC, Yu J, Lee K, Kang WC and Moon J. Routine Indwelling Urethral Catheterization in Acute Heart Failure Patients Is Associated With Increased Urinary Tract Complications Without Improved Heart Failure Outcomes. Circ J. 2018;82:1632-1639. [First author, IF 2.7]
2018 Serpooshan V*, Sheibani S*, Pushparaj P*, Wojcik M*, Jang AY*, Santoso MR, Jang JH, Huang H, Safavi-Sohi R, Haghjoo N, Nejadnik H, Aghaverdi H, Vali H, Kinsella JM, Presley J, Xu K, Yang PC and Mahmoudi M. Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface. ACS Nano. 2018;12:2253-2266. [Co-first author, IF 13.9]
More